ASLAN Pharmaceuticals to Present at H.C. Wainwright 23rd Annual Global Investment Conference
ASLAN Pharmaceuticals (Nasdaq:ASLN), a biopharmaceutical company focused on immunology, announced that CEO Dr. Carl Firth will present at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ASLAN Pharmaceuticals (Nasdaq:ASLN), a biopharmaceutical company focused on immunology, announced that CEO Dr. Carl Firth will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021. The conference runs from September 13-15, 2021. An on-demand recording of Dr. Firth's presentation will be available on September 13 at 7:00 AM ET on ASLAN’s Investor Relations website. ASLAN is developing innovative treatments, including ASLAN004 for atopic dermatitis and ASLAN003 for autoimmune diseases.
Details
News Market Reaction – ASLN
The recorded move for ASLN in the trading session of this news was +3.31%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MENLO PARK, Calif. and SINGAPORE, Sept. 09, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, is scheduled to give a company presentation at the H.C. Wainwright 23rd Annual Global Investment Conference on 13 September, 2021. The conference will be held from September 13 to September 15, 2021.
An on demand recording of the presentation will be made available on 13 September at 7:00am ET in the Investor Relations section of ASLAN’s website at www.ir.aslanpharma.com and at the following link: https://journey.ct.events/view/1b10cdbc-a1e0-4f84-b475-753e1832a13a
Media and IR contacts
| Emma Thompson Spurwing Communications Tel: +65 6206 7350 Email: ASLAN@spurwingcomms.com | Ashley R. Robinson LifeSci Advisors, LLC Tel: +1 (617) 430-7577 Email: arr@lifesciadvisors.com |
About ASLAN Pharmaceuticals
ASLAN Pharmaceuticals (Nasdaq:ASLN) is a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN is currently evaluating ASLAN004, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, a potent oral inhibitor of DHODH, which is being developed for autoimmune disease. ASLAN has a team in Menlo Park, California, and in Singapore. For additional information please visit www.aslanpharma.com or follow ASLAN on LinkedIn.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.